Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy AssetBusiness Wire • 01/13/26
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investmentGlobeNewsWire • 01/09/26
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients payWSJ • 12/19/25
Salesforce's Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement GloballyBusiness Wire • 12/17/25
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood DisorderBenzinga • 12/09/25
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly dosesGlobeNewsWire • 12/09/25
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 yearsGlobeNewsWire • 12/09/25